

# Carolina Garcia-Vidal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6661499/publications.pdf>

Version: 2024-02-01

185  
papers

8,551  
citations

53789

45  
h-index

54911

84  
g-index

200  
all docs

200  
docs citations

200  
times ranked

9269  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of systemic steroids in patients with severe community-acquired pneumonia. <i>European Respiratory Journal</i> , 2007, 30, 951-956.	6.7	1,178
2	Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 83-88.	6.0	636
3	Estimating the Burden of Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis of Diagnostic Techniques. <i>PLoS ONE</i> , 2013, 8, e60273.	2.5	329
4	Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 657-663.	3.0	208
5	Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. <i>Autoimmunity Reviews</i> , 2020, 19, 102429.	5.8	197
6	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	17.0	189
7	Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2120.	4.1	168
8	Bacteraemia due to extended-spectrum $\beta$ -lactamase-producing <i>Escherichia coli</i> (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 333-341.	3.0	158
9	<i>Pseudomonas aeruginosa</i> in patients hospitalised for COPD exacerbation: a prospective study. <i>European Respiratory Journal</i> , 2009, 34, 1072-1078.	6.7	141
10	Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. <i>Critical Care</i> , 2011, 15, R96.	5.8	121
11	An update on <i>Legionella</i> . <i>Current Opinion in Infectious Diseases</i> , 2010, 23, 152-157.	3.1	115
12	Fungal co-infection in COVID-19 patients: Should we be concerned?. <i>Revista Iberoamericana De Micologia</i> , 2020, 37, 41-46.	0.9	113
13	Effect of a 3-Step Critical Pathway to Reduce Duration of Intravenous Antibiotic Therapy and Length of Stay in Community-Acquired Pneumonia. <i>Archives of Internal Medicine</i> , 2012, 172, 922-8.	3.8	108
14	Early mortality in patients with community-acquired pneumonia: causes and risk factors. <i>European Respiratory Journal</i> , 2008, 32, 733-739.	6.7	105
15	Community-Acquired <i>Legionella pneumophila</i> Pneumonia. <i>Medicine (United States)</i> , 2013, 92, 51-60.	1.0	102
16	Predictive factors, microbiology and outcome of patients with parapneumonic effusion. <i>European Respiratory Journal</i> , 2011, 38, 1173-1179.	6.7	100
17	Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. <i>Thorax</i> , 2010, 65, 77-81.	5.6	97
18	Prognostic value of serum albumin levels in hospitalized adults with community-acquired pneumonia. <i>Journal of Infection</i> , 2013, 66, 415-423.	3.3	97

#	ARTICLE	IF	CITATIONS
19	Invasive Aspergillosis Complicating Pandemic Influenza A (H1N1) Infection in Severely Immunocompromised Patients. <i>Clinical Infectious Diseases</i> , 2011, 53, e16-e19.	5.8	91
20	Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2009, 28, 331-337.	2.9	90
21	&lt;b&gt;&lt;i&gt;Pseudomonas aeruginosa&lt;/i&gt;&lt;/b&gt; and Mortality after Hospital Admission for Chronic Obstructive Pulmonary Disease. <i>Respiration</i> , 2012, 84, 36-43.	2.6	89
22	8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. <i>Lancet Oncology</i> , The, 2021, 22, e254-e269.	10.7	89
23	Epidemiology, clinical features and outcomes of pneumonia in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2899-2906.	0.7	88
24	Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients. <i>Bone Marrow Transplantation</i> , 2014, 49, 824-830.	2.4	87
25	Pathogenesis of invasive fungal infections. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 270-276.	3.1	85
26	Biomarkers for predicting short-term mortality in community-acquired pneumonia: A systematic review and meta-analysis. <i>Journal of Infection</i> , 2016, 72, 273-282.	3.3	84
27	Low incidence of multidrug-resistant organisms in patients with healthcare-associated pneumonia requiring hospitalization. <i>Clinical Microbiology and Infection</i> , 2011, 17, 1659-1665.	6.0	81
28	Community-Acquired Pneumonia in Patients With Liver Cirrhosis. <i>Medicine (United States)</i> , 2011, 90, 110-118.	1.0	78
29	Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia. <i>Journal of Infection</i> , 2013, 66, 27-33.	3.3	76
30	Artificial intelligence to support clinical decision-making processes. <i>EBioMedicine</i> , 2019, 46, 27-29.	6.1	76
31	Recent improvement in long-term survival after a COPD hospitalisation. <i>Thorax</i> , 2010, 65, 298-302.	5.6	69
32	Management of community-acquired pneumonia in older adults. <i>Therapeutic Advances in Infectious Disease</i> , 2014, 2, 3-16.	1.8	68
33	Epidemiology, antibiotic therapy and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in cancer patients. <i>Supportive Care in Cancer</i> , 2014, 22, 603-610.	2.2	67
34	Inappropriate Empirical Antibiotic Treatment in High-risk Neutropenic Patients With Bacteremia in the Era of Multidrug Resistance. <i>Clinical Infectious Diseases</i> , 2020, 70, 1068-1074.	5.8	66
35	8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation. <i>Lancet Oncology</i> , The, 2021, 22, e270-e280.	10.7	65
36	Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. <i>Infection</i> , 2021, 49, 215-231.	4.7	63

#	ARTICLE	IF	CITATIONS
37	Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli. <i>Respirology</i> , 2009, 14, 105-111.	2.3	62
38	Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance. <i>PLoS ONE</i> , 2018, 13, e0199531.	2.5	60
39	Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 520-524.	2.5	59
40	Aetiology of, and risk factors for, recurrent community-acquired pneumonia. <i>Clinical Microbiology and Infection</i> , 2009, 15, 1033-1038.	6.0	58
41	Increase in Bloodstream Infection Due to Vancomycin-Susceptible <i>Enterococcus faecium</i> in Cancer Patients: Risk Factors, Molecular Epidemiology and Outcomes. <i>PLoS ONE</i> , 2013, 8, e74734.	2.5	55
42	Factors influencing mortality in neutropenic patients with haematologic malignancies or solid tumours with bloodstream infection. <i>Clinical Microbiology and Infection</i> , 2015, 21, 583-590.	6.0	51
43	Antibiotic selection in the treatment of acute invasive infections by <i>Pseudomonas aeruginosa</i> : Guidelines by the Spanish Society of Chemotherapy. <i>Revista Espanola De Quimioterapia</i> , 2018, 31, 78-100.	1.3	48
44	Rainfall Is a Risk Factor for Sporadic Cases of <i>Legionella pneumophila</i> Pneumonia. <i>PLoS ONE</i> , 2013, 8, e61036.	2.5	47
45	Executive summary of clinical practice guideline for the management of invasive diseases caused by <i>Aspergillus</i> : 2018 Update by the GEMICOMED-SEIMC/REIPI. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 535-541.	0.5	46
46	COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. <i>Blood Advances</i> , 2022, 6, 2427-2433.	5.2	46
47	Causes of Death in a Contemporary Cohort of Patients with Invasive Aspergillosis. <i>PLoS ONE</i> , 2015, 10, e0120370.	2.5	45
48	Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia. <i>European Respiratory Journal</i> , 2018, 51, 1702215.	6.7	45
49	Clinical Features, Etiology and Outcomes of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease. <i>PLoS ONE</i> , 2014, 9, e105854.	2.5	45
50	Breakthrough candidaemia in the era of broad-spectrum antifungal therapies. <i>Clinical Microbiology and Infection</i> , 2016, 22, 181-188.	6.0	44
51	Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 547-5553.	3.0	44
52	Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant <i>Pseudomonas aeruginosa</i> . <i>Journal of Global Antimicrobial Resistance</i> , 2018, 15, 136-139.	2.2	43
53	Statins for community-acquired pneumonia: current state of the science. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2010, 29, 143-152.	2.9	42
54	The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. <i>BMJ Open</i> , 2015, 5, e006251-e006251.	1.9	42

#	ARTICLE	IF	CITATIONS
55	Community-acquired pneumonia as an emergency condition. <i>Current Opinion in Critical Care</i> , 2018, 24, 531-539.	3.2	41
56	Bacterial co-infection at hospital admission in patients with COVID-19. <i>International Journal of Infectious Diseases</i> , 2022, 118, 197-202.	3.3	41
57	Declining mortality among hospitalized patients with community-acquired pneumonia. <i>Clinical Microbiology and Infection</i> , 2016, 22, 567.e1-567.e7.	6.0	40
58	Current time-to-positivity of blood cultures in febrile neutropenia: a tool to be used in stewardship de-escalation strategies. <i>Clinical Microbiology and Infection</i> , 2019, 25, 447-453.	6.0	40
59	Clinical features and outcomes of Legionnaires' disease in solid organ transplant recipients. <i>Transplant Infectious Disease</i> , 2009, 11, 78-82.	1.7	38
60	Levofloxacin versus azithromycin for treating legionella pneumonia: a propensity score analysis. <i>Clinical Microbiology and Infection</i> , 2017, 23, 653-658.	6.0	38
61	A propensity score-matched analysis of mortality in solid organ transplant patients with COVID-19 compared to non-solid organ transplant patients. <i>PLoS ONE</i> , 2021, 16, e0247251.	2.5	38
62	Environmental variables associated with an increased risk of invasive aspergillosis. <i>Clinical Microbiology and Infection</i> , 2014, 20, O939-O945.	6.0	37
63	Personalized Therapy Approach for Hospitalized Patients with Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2022, 74, 127-132.	5.8	36
64	Development of a severity of disease score and classification model by machine learning for hospitalized COVID-19 patients. <i>PLoS ONE</i> , 2021, 16, e0240200.	2.5	36
65	Clinical Features, Etiology, and Outcomes of Community-Acquired Pneumonia in Patients With Diabetes Mellitus. <i>Medicine (United States)</i> , 2013, 92, 42-50.	1.0	35
66	Molecular Epidemiology of Nontypeable <i>Haemophilus influenzae</i> Causing Community-Acquired Pneumonia in Adults. <i>PLoS ONE</i> , 2013, 8, e82515.	2.5	35
67	Trends in mortality of hospitalised COVID-19 patients: A single centre observational cohort study from Spain. <i>Lancet Regional Health - Europe</i> , 2021, 3, 100041.	5.6	35
68	Incidence, timing and risk factors associated with 1-year mortality after hospitalization for community-acquired pneumonia. <i>Journal of Infection</i> , 2014, 68, 534-541.	3.3	34
69	Effect of Combined $\beta$ -Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia. <i>Chest</i> , 2019, 155, 795-804.	0.8	34
70	Changing epidemiology of bloodstream infection in a 25-years hematopoietic stem cell transplant program: current challenges and pitfalls on empiric antibiotic treatment impacting outcomes. <i>Bone Marrow Transplantation</i> , 2020, 55, 603-612.	2.4	33
71	Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	33
72	Early and Late Treatment Failure in Community-Acquired Pneumonia. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009, 30, 154-160.	2.1	32

#	ARTICLE	IF	CITATIONS
73	A prospective cohort study of healthcare visits and rehospitalizations after discharge of patients with community-acquired pneumonia. <i>Respirology</i> , 2011, 16, 1119-1126.	2.3	32
74	What is healthcare-associated pneumonia and how is it managed?. <i>Current Opinion in Infectious Diseases</i> , 2008, 21, 168-173.	3.1	30
75	Timing of antibiotic administration and outcomes of hospitalized patients with community-acquired and healthcare-associated pneumonia. <i>Clinical Microbiology and Infection</i> , 2012, 18, 1149-1155.	6.0	30
76	Clinical features, aetiology and outcome of bacteraemic pneumonia in neutropenic cancer patients. <i>Respirology</i> , 2016, 21, 1411-1418.	2.3	30
77	Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3315-3327.	3.0	30
78	Can Artificial Intelligence Improve the Management of Pneumonia. <i>Journal of Clinical Medicine</i> , 2020, 9, 248.	2.4	30
79	Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3296-3302.	3.0	30
80	Do high MICs predict the outcome in invasive fusariosis?. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1063-1069.	3.0	28
81	Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia. <i>PLoS ONE</i> , 2017, 12, e0182436.	2.5	28
82	Impact of Empirical Antibiotic Regimens on Mortality in Neutropenic Patients with Bloodstream Infection Presenting with Septic Shock. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0174421.	3.2	28
83	Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia. <i>PLoS ONE</i> , 2018, 13, e0200504.	2.5	27
84	Predictors of multidrug-resistant <i>Pseudomonas aeruginosa</i> in neutropenic patients with bloodstream infection. <i>Clinical Microbiology and Infection</i> , 2020, 26, 345-350.	6.0	27
85	Clinical and microbiological epidemiology of <i>Streptococcus pneumoniae</i> bacteremia in cancer patients. <i>Journal of Infection</i> , 2012, 65, 521-527.	3.3	26
86	Usefulness of guideline recommendations for prognosis in patients with candidemia. <i>Medical Mycology</i> , 2019, 57, 659-667.	0.7	24
87	Invasive aspergillosis in solid organ transplant patients: diagnosis, prophylaxis, treatment, and assessment of response. <i>BMC Infectious Diseases</i> , 2021, 21, 296.	2.9	24
88	Current clinical management of Legionnaires' disease. <i>Expert Review of Anti-Infective Therapy</i> , 2006, 4, 995-1004.	4.4	23
89	Fungal postoperative spondylodiscitis due to <i>Scedosporium prolificans</i> . <i>Spine Journal</i> , 2009, 9, e1-e7.	1.3	23
90	Mortality of Tuberculosis in Very Old People. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 18-22.	2.6	23

#	ARTICLE	IF	CITATIONS
91	Short-Term Peripheral Venous Catheter-Related Bloodstream Infections: Evidence for Increasing Prevalence of Gram-Negative Microorganisms from a 25-Year Prospective Observational Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	23
92	Changing Epidemiology of Invasive Fungal Disease in Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 848.	3.5	23
93	Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired Pneumonia. <i>Journal of Clinical Medicine</i> , 2019, 8, 961.	2.4	22
94	Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematological malignancies. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 174-181.	0.5	22
95	Prediction of prognosis by markers in community-acquired pneumonia. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 917-929.	4.4	20
96	Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3443-3452.	3.0	20
97	Antimicrobial Resistance Among <i>Streptococcus pneumoniae</i> . , 2018, , 13-38.		20
98	Real-life use of remdesivir in hospitalized patients with COVID-19. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 136-140.	1.3	20
99	Lymphopenia Is Associated With Poor Outcomes of Patients With Community-Acquired Pneumonia and Sepsis. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab169.	0.9	20
100	A simple prediction score for estimating the risk of candidaemia caused by fluconazole non-susceptible strains. <i>Clinical Microbiology and Infection</i> , 2015, 21, 684.e1-684.e9.	6.0	19
101	Echinocandins Compared to Fluconazole for Candidemia of a Urinary Tract Source: A Propensity Score Analysis. <i>Clinical Infectious Diseases</i> , 2017, 64, 1374-1379.	5.8	19
102	Factors associated with the development of septic shock in patients with candidemia: a post hoc analysis from two prospective cohorts. <i>Critical Care</i> , 2020, 24, 117.	5.8	19
103	Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). <i>Leukemia</i> , 2022, 36, 1215-1226.	7.2	19
104	Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: a Propensity-Matched Cohort Study (AMINOLACTAM Study). <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0004521.	3.2	18
105	An evidence-based bundle improves the quality of care and outcomes of patients with candidaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 730-737.	3.0	17
106	Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain. <i>BMC Pharmacology &amp; Toxicology</i> , 2014, 15, 52.	2.4	16
107	Unusual forms of subacute invasive pulmonary aspergillosis in patients with solid tumors. <i>Journal of Infection</i> , 2014, 69, 387-395.	3.3	16
108	Changing epidemiology of catheter-related bloodstream infections in neutropenic oncohematological patients. <i>PLoS ONE</i> , 2021, 16, e0251010.	2.5	16

#	ARTICLE	IF	CITATIONS
109	Peripheral facial palsy after varicella. Report of two cases and review of the literature. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2010, 28, 504-508.	0.5	15
110	Advances in antibiotic therapy for community-acquired pneumonia. <i>Current Opinion in Pulmonary Medicine</i> , 2013, 19, 209-215.	2.6	15
111	Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysis. <i>Journal of Infection</i> , 2018, 76, 342-347.	3.3	15
112	Community-acquired bacterial pneumonia in adult HIV-infected patients. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 579-588.	4.4	15
113	Recomendaciones para la vacunación en pacientes con esclerosis múltiple candidatos a terapias inmunosupresoras: documento de consenso español. <i>Neurología</i> , 2021, 36, 50-60.	0.7	15
114	Effect of Statin Use on Outcomes of Adults with Candidemia. <i>PLoS ONE</i> , 2013, 8, e77317.	2.5	15
115	Impact of SARS-CoV-2 viral load and duration of symptoms before hospital admission on the mortality of hospitalized COVID-19 patients. <i>Infection</i> , 2022, 50, 1321-1328.	4.7	15
116	COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). <i>Haematologica</i> , 2023, 108, 22-33.	3.5	15
117	Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2010, 29, 1243-1251.	2.9	14
118	Candidemia in solid organ transplant recipients in Spain: Epidemiological trends and determinants of outcome. <i>Transplant Infectious Disease</i> , 2019, 21, e13195.	1.7	14
119	Performance of differential time to positivity as a routine diagnostic test for catheter-related bloodstream infections: a single-centre experience. <i>Clinical Microbiology and Infection</i> , 2020, 26, 383.e1-383.e7.	6.0	14
120	Fungal infections following treatment with monoclonal antibodies and other immunomodulatory therapies. <i>Revista Iberoamericana De Micología</i> , 2020, 37, 5-16.	0.9	14
121	Machine Learning to Assess the Risk of Multidrug-Resistant Gram-Negative Bacilli Infections in Febrile Neutropenic Hematological Patients. <i>Infectious Diseases and Therapy</i> , 2021, 10, 971-983.	4.0	14
122	Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia. <i>Chest</i> , 2017, 151, 1311-1319.	0.8	13
123	The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia. <i>Archivos De Bronconeumología</i> , 2021, 57, 79-82.	0.8	13
124	Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia. <i>ERJ Open Research</i> , 2021, 7, 00888-2020.	2.6	13
125	Promoting the use of social networks in pneumonia. <i>Pneumonia (Nathan Qld)</i> , 2020, 12, 3.	6.1	12
126	Detection of human cytomegalovirus in bronchoalveolar lavage of intensive care unit patients. <i>European Respiratory Journal</i> , 2018, 51, 1701332.	6.7	11



#	ARTICLE	IF	CITATIONS
127	Deleterious Effect of Steroids on Cytomegalovirus Infection Rate after Allogeneic Stem Cell Transplantation Depends on Pretransplant Cytomegalovirus Serostatus of Donors and Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2088-2093.	2.0	11
128	Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab250.	0.9	11
129	Prolonged viral replication in patients with hematologic malignancies hospitalized with COVID-19. <i>Haematologica</i> , 2022, 107, 1731-1735.	3.5	11
130	C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19. <i>Scientific Reports</i> , 2022, 12, 5250.	3.3	11
131	Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to <i>Pseudomonas aeruginosa</i> in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH) <i>Tj ETQq1 1 0.784314 rgBñi/Overlo</i>	3.4	11
132	Impact of an Educational Program to Reduce Healthcare Resources in Community-Acquired Pneumonia: The EDUCAP Randomized Controlled Trial. <i>PLoS ONE</i> , 2015, 10, e0140202.	2.5	10
133	Effect of statins on outcomes in immunosuppressed patients with bloodstream infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2011, 30, 77-82.	2.9	9
134	Impact of pre-hospital antibiotic use on community-acquired pneumonia. <i>Clinical Microbiology and Infection</i> , 2014, 20, O531-O537.	6.0	9
135	Community-Acquired <i>Legionella</i> Pneumonia in Human Immunodeficiency Virus-Infected Adult Patients: A Matched Case-Control Study. <i>Clinical Infectious Diseases</i> , 2018, 67, 958-961.	5.8	9
136	Early, short and long-term mortality in community-acquired pneumonia. <i>Annals of Research Hospitals</i> , 0, 2, 5-5.	0.0	9
137	Acute liver failure due to visceral leishmaniasis in Barcelona: a case report. <i>BMC Infectious Diseases</i> , 2019, 19, 874.	2.9	9
138	Posaconazole salvage therapy: The Posifi study. <i>Mycoses</i> , 2019, 62, 526-533.	4.0	9
139	Methicillin-susceptible staphylococcus aureus in community-acquired pneumonia: Risk factors and outcomes. <i>Journal of Infection</i> , 2021, 82, 76-83.	3.3	9
140	Risk Factors for Mortality in Hematopoietic Stem Cell Transplantation Recipients with Bloodstream Infection: Points To Be Addressed by Future Guidelines. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 501.e1-501.e6.	1.2	9
141	Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19. <i>Transfusion</i> , 2022, 62, 974-981.	1.6	9
142	Impact of intensifying primary antibiotic prophylaxis in at-home autologous stem cell transplantation program for lymphoma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1565-1574.	1.3	8
143	Primary immunodeficiency and chronic mucocutaneous candidiasis: pathophysiological, diagnostic, and therapeutic approaches.. <i>Allergologia Et Immunopathologia</i> , 2021, 49, 118-127.	1.7	8
144	Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant. <i>Mycoses</i> , 2017, 60, 79-88.	4.0	7

#	ARTICLE	IF	CITATIONS
145	Antibiotic-resistant microorganisms in patients with bloodstream infection of intraabdominal origin: risk factors and impact on mortality. <i>Infection</i> , 2021, 49, 693-702.	4.7	7
146	Multidrug-resistant, gram-negative infections in high-risk haematologic patients: an update on epidemiology, diagnosis and treatment. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 314-322.	3.1	7
147	Emergence of Progressive Mutations in SARS-CoV-2 From a Hematologic Patient With Prolonged Viral Replication. <i>Frontiers in Microbiology</i> , 2022, 13, 826883.	3.5	7
148	Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysisâ€™ authorsâ€™ response. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1732-1733.	3.0	6
149	Efficacy of extended infusion of Î²-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE). <i>Trials</i> , 2020, 21, 412.	1.6	6
150	Defining Community-Acquired Pneumonia as a Public Health Threat: Arguments in Favor from Spanish Investigators. <i>Medical Sciences (Basel, Switzerland)</i> , 2020, 8, 6.	2.9	6
151	PET/CT added to Duke criteria facilitates diagnosis and monitoring of long-term suppressive therapy of prosthetic endocarditis. <i>Infectious Diseases</i> , 2017, 49, 698-701.	2.8	5
152	Difficult to treat microorganisms in patients aged over 80 years with community-acquired pneumonia: the prevalence of PES pathogens. <i>European Respiratory Journal</i> , 2020, 56, 2000773.	6.7	5
153	Impact of Inflammatory Response Modifiers on the Incidence of Hospital-Acquired Infections in Patients with COVID-19. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1407-1418.	4.0	5
154	Safety and efficacy of intravenously administered cidofovir in adult haematopoietic cell transplant recipients: a retrospective multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3020-3028.	3.0	5
155	Resistance to empirical Î²-lactams recommended in febrile neutropenia guidelines in Gram-negative bacilli bloodstream infections in Spain: a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2017-2023.	3.0	5
156	Paradoxical Reaction of Multiple Cerebral Tuberculomas. <i>Mayo Clinic Proceedings</i> , 2008, 83, 264.	3.0	4
157	Defining standards of CARE for invasive fungal diseases in solid organ transplant patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, ii16-ii20.	3.0	4
158	Echinocandins for Candidemia. <i>New England Journal of Medicine</i> , 2006, 355, 2791-2792.	27.0	3
159	Should Health Care Systems and Health Care Providers Implement a New Pathway for Hospitalized Patients With Community-Acquired Pneumonia?â€™ Reply. <i>Archives of Internal Medicine</i> , 2012, 172, 1771.	3.8	3
160	Gustatory and olfactory dysfunctions in hospitalised patients with COVID-19 pneumonia: a prospective study. <i>BMJ Open</i> , 2021, 11, e040775.	1.9	3
161	Ceftobiprole for the treatment of pneumonia. <i>Revista Espanola De Quimioterapia</i> , 2019, 32 Suppl 3, 17-23.	1.3	3
162	Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin. <i>Expert Review of Hematology</i> , 2022, 15, 203-214.	2.2	3

#	ARTICLE	IF	CITATIONS
163	Up-to-Date Infection Control Practices for Febrile Neutropenic Patients. Current Treatment Options in Infectious Diseases, 2020, 12, 77-86.	1.9	2
164	Factors Associated With Short-Term Eradication of Rectal Colonization by KPC-2 Producing Klebsiella pneumoniae in an Outbreak Setting. Frontiers in Microbiology, 2021, 12, 630826.	3.5	2
165	Clinical Characteristics and Outcome of Bloodstream Infections in HIV-Infected Patients with Cancer and Febrile Neutropenia: A Case-Control Study. Infectious Diseases and Therapy, 2021, 10, 955-970.	4.0	2
166	COVID-19 and fungal infections: Etiopathogenesis and therapeutic implications. Revista Espanola De Quimioterapia, 2021, 34, 72-75.	1.3	2
167	Profile of patients with COVID-19 treated in Spanish emergency departments during the 2020 pandemic. Emergencias, 2020, 32, 225-226.	0.6	2
168	Clinical Presentation and Outcome of COVID-19 in a Latin American Versus Spanish Population: Matched Case-Control Study. Infectious Diseases and Therapy, 2022, 11, 1243-1251.	4.0	2
169	When and which patients should receive remdesivir?. Lancet, The, 2022, 399, 1918-1920.	13.7	2
170	Artritis reumatoide y tropismo infeccioso. Seminarios De La Fundaci3n Espaola De Reumatologaa, 2007, 8, 68-87.	0.1	1
171	Exaggerated Insect Bite Reaction Related to Chronic Leukemia. Mayo Clinic Proceedings, 2013, 88, e37.	3.0	1
172	Mortality of CAP reduced in the UK: is this enough?. Thorax, 2016, 71, 979-980.	5.6	1
173	Has Mortality of Community-Acquired Pneumonia Really Reduced?. Clinical Pulmonary Medicine, 2017, 24, 258-262.	0.3	1
174	THU0683â€¦COVERAGE, PREDICTORS OF VACCINATION AND FREQUENCY OF SEVERE INFECTIONS DUE TO STREPTOCOCCUS PNEUMONIAE IN A COHORT OF PATIENTS WITH CHRONIC INFLAMMATORY ARTHRITIS WITHIN AN EIGHTEEN-YEAR PERIOD. , 2019, , .		1
175	Combination antifungal therapy for breakthrough invasive mould disease in patients with haematological malignancies: when management reasoning eclipses evidence-based medicine. Journal of Antimicrobial Chemotherapy, 2020, 75, 3096-3098.	3.0	1
176	Prophylaxis of mould infections. Revista Espanola De Quimioterapia, 2019, 32 Suppl 2, 59-62.	1.3	1
177	Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis. European Journal of Clinical Microbiology and Infectious Diseases, 2022, 41, 271-279.	2.9	1
178	Cytokine response as a biomarker for early diagnosis and outcome prediction of stem cell transplant recipients and acute leukemia patients with invasive aspergillosis. Medical Mycology, 2022, 60, .	0.7	1
179	Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia. Journal of Clinical Medicine, 2019, 8, 1150.	2.4	0
180	Pulse oximetry is an essential tool that saves lives: a call for standardisation. European Respiratory Journal, 2021, 57, 2100815.	6.7	0

#	ARTICLE	IF	CITATIONS
181	Macrolide combination therapy for hospitalised CAP patients? An individualised approach supported by machine learning. <i>European Respiratory Journal</i> , 2019, 54, 1902111.	6.7	0
182	Top-ten papers in fungal infection (2015-2017). <i>Revista Espanola De Quimioterapia</i> , 2018, 31 Suppl 1, 32-34.	1.3	0
183	1598. Clinical implications of azole-resistant vs. azole-susceptible invasive aspergillosis in hematological malignancy (CLARITY) – a multicenter study. <i>Open Forum Infectious Diseases</i> , 2020, 7, S795-S796.	0.9	0
184	Main Acquired Risk Factors of Different Fungal Diseases. , 2022, , .		0
185	Correction to: Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	0